PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach

Peripheral immune-checkpoint blockade with mAbs to programmed cell death receptor-1 (PD-1) (either nivolumab or pembrolizumab) or PD-Ligand-1 (PD-L1) (atezolizumab, durvalumab, or avelumab) alone or in combination with doublet chemotherapy represents an expanding treatment strategy for metastatic no...

Descripción completa

Detalles Bibliográficos
Autores principales: Fameli, Antonella, Nardone, Valerio, Shekarkar Azgomi, Mojtaba, Bianco, Giovanna, Gandolfo, Claudia, Oliva, Bianca Maria, Monoriti, Marika, Saladino, Rita Emilena, Falzea, Antonella, Romeo, Caterina, Calandruccio, Natale Daniele, Azzarello, Domenico, Giannicola, Rocco, Pirtoli, Luigi, Giordano, Antonio, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Cusi, Maria Grazia, Mutti, Luciano, Botta, Cirino, Correale, Pierpaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515511/
https://www.ncbi.nlm.nih.gov/pubmed/36185285
http://dx.doi.org/10.3389/fonc.2022.911579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515511/
https://www.ncbi.nlm.nih.gov/pubmed/36185285
http://dx.doi.org/10.3389/fonc.2022.911579

Ejemplares similares